Reuters (12/5, Beasley, Steenhuysen, Mishra) reports Biogen “presented new data on its experimental Alzheimer’s drug aducanumab that eased concerns raised by some experts but still left many questions unanswered as the company made its case about why it plans to seek U.S. approval after declaring the drug a failure in March.” The article says that the FDA is expected to review the drug next year. The AP (12/5, Marchione) reports Biogen’s new data was presented at a conference and “may help explain why one study of the experimental medicine succeeded and another failed.” The article says that the company stopped studies on the drug earlier this year, but then said it was effective at a higher dose later in the year. (SOURCE: APA Headlines)